NASDAQ: ALMRAlamar Biosciences Inc Stock
$21.49+0.55 (+2.63%)
Updated Jun 4, 2026
ALMR Price
$21.49
Fair Value Price
N/A
Market Cap
$1.49B
52 Week Low
$18.85
52 Week High
$27.20
P/E
N/A
P/B
-8.36x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.73
Operating Cash Flow
N/A
Beta
1.34
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALMR Overview
Alamar Biosciences is a commercial-stage proteomics company focused on ultra-sensitive, multiplexed protein detection for research and future clinical applications. Its platform combines proprietary instruments, consumables, and software to provide an end-to-end system for measuring multiple low-abundance proteins across research and potential clinical applications.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALMR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
ALMR
Ranked#69 of 96
Ranked#69 of 96
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.70 | A | |
| $36.72 | A | |
| $25.17 | A |
Be the first to know about important ALMR news, forecast changes, insider trades & much more!
ALMR News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALMR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALMR's short-term assets ($141.47M) exceed its short-term liabilities ($24.05M)
Short-term Liabilities Financials
ALMR's short-term assets ($141.47M) exceed its long-term liabilities ($105.48M)
Long-term Liabilities Financials
ALMR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more ALMR due diligence checks available for Premium users.
Valuation
ALMR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-8.36x
Industry
3.02x
ALMR's financial health
Profit margin
Revenue
$26.0M
Net Income
-$21.3M
Profit Margin
-81.9%
Assets to liabilities
Assets
$186.5M
Liabilities
$129.5M
Debt to equity
-0.73
ALMR's short-term assets ($141.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALMR's short-term assets ($141.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALMR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALMR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.3M
Investing
-$778.0k
Financing
$55.8M
ALMR vs Medical Device Stocks
Alamar Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.